<DOC>
	<DOCNO>NCT02706015</DOCNO>
	<brief_summary>This study evaluate non-inferiority Cefaliv® compare Neosaldina® treatment migraine attack two hundred sixteen adult sexes age eighteen sixty five year old . The first Half participant receive Cefaliv® , half receive Neosaldina® .</brief_summary>
	<brief_title>Cefaliv® Compared Neosaldina® Treatment Migraine Attacks</brief_title>
	<detailed_description>Cefaliv® combination 3 drug : dihydroergotamine mesylate , dipyrone sodium , caffeine . The dihydroergotamine mesylate interacts serotonergic , dopaminergic noradrenergic receptor , 's mechanism totally know . The dipyrone non-steroidal antiinflammatory analgesic , antiinflammatory antipyretic effect . And caffeine present mechanisms totally clear , may relieve pain activate central noradenosine pathway ( pain suppress system ) .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Dihydroergotamine</mesh_term>
	<mesh_term>Dipyrone</mesh_term>
	<criteria>1 . Subjects sex ; 2 . Age old equal 18 young 66 year symptoms migraine headache 50 year age ; 3 . Presence migraine headache without aura symptom , least 03 month prior study , criterion define International Classification Headache Disorders ( ICHD ) II , 2004 International Headache Society ( IHS ) Annex I ; 4 . Subjects experience 26 migraine attack per month mild moderate pain intensity last 3 month prior screen visit ; 5 . Subjects able distinguish migraine attack type headache ; 6 . Aptitude understand consent participate clinical study , manifest signing Informed Consent Informed ( IFC ) ; 1 . Any clinical finding ( clinical evaluation / physical ) interpret Investigator risk participant clinical trial ; 2 . Subjects recent episode headache , frequency equal high 15 daily episode per month , 3 month prior screen visit ; 3 . Subjects headache history define ICHDII criterion , 2004 IHS ( International Headache Society ) rat : Typical aura nonmigraine headache ; Typical aura without headache ; Familial Hemiplegic Migraine ( FHM ) ; Sporadic Hemiplegic Migraine ; Basilar type Migraine ; 4 . Any laboratorial finding Investigator consider risk subject study ; 5 . Hypersensitivity drug component , study ; 6 . Women pregnancy nursing period ; 7 . Women reproductive age agree use contraception acceptable [ oral contraceptive , injectable contraceptive , intrauterine device ( IUD ) , hormonal implant , barrier method , hormonal patch tubal ligation ] ; surgically sterile ( bilateral oophorectomy hysterectomy ) , postmenopausal least one ( 01 ) year sexual abstinence ; 8 . Inability understand answer functional categorical scale study , diary symptom , accompany assist him/her ; 9 . History abuse , accord principal investigator , alcohol , opioids , barbiturate , benzodiazepine illicit drug last 02 year , abuse drug headache include ergotamine narcotic last 03 month ; 10 . Subjects prolonged hypotension , shock , sepsis , pheochromocytoma , hemorrhage , mechanical obstruction perforation gastrointestinal tract ; 11 . Subjects history epilepsy presence psychiatric illness kind , opinion investigator , may interfere adherence treatment ; 12 . Subjects malignant disease less five year , five year , without documentation remission/cure . As example : melanoma , leukemia , lymphoma , myeloproliferative disease renal cell carcinoma length exclude . Exceptions : Subjects basal cell skin cancer , squamous cell , cervical cancer situ may eligible . 13 . Subjects use preventive treatment change dose last 3 month screen visit ( V0 ) ; 14 . Subjects make interruption prophylactic treatment , last 30 day prior screen visit ( V0 ) ; 15 . Subjects hepatic renal failure ; 16 . Subjects research participate clinical trial protocol last twelve ( 12 ) month ( National Board Health Resolution 251 07 August 1997 , Part III , subitem J ) , unless investigator considers may direct benefit ; 17 . Subjects prohibit medication describe item 10.2 Protocol . 18 . Subjects previous diagnosis uncontrolled hypertension ; 19 . Subjects history peripheral vascular disease ; acute myocardial infarction , angina pectoris ischemic heart disease ; 20 . Subjects allergy pyrazolones ( eg phenazone , propyphenazone ) pyrazolidines ( eg phenylbutazone , oxyphenbutazone ) submit agranulocytosis relation medicine ; 21 . Subjects history metabolic disorder porphyria congenital deficiency glucose6phosphate dehydrogenase ; 22 . Subjects history alteration bone marrow function hematopoietic system diseases ; 23 . Subjects history bronchospasm allergic reaction ( rhinitis , urticaria , angioedema ) induce aspirin , acetaminophen , antiinflammatory medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Headache</keyword>
	<keyword>Aura</keyword>
	<keyword>Migraine</keyword>
</DOC>